Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Andrew Allan Hertler"'
Publikováno v:
Journal of Clinical Oncology. 40:129-129
129 Background: The use of bone-modifying agents (BMAs) in multiple myeloma is gold standard. Benefits include prevention of skeletal-related events, reduction in bone pain, and improved progression-free survival. Guidelines recommend that patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1638c4d07530fe6548d64156239d6a9f
https://doi.org/10.1200/jco.2022.40.28_suppl.129
https://doi.org/10.1200/jco.2022.40.28_suppl.129
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:CLO19-030
Background: Lung cancer is the leading cause of death in the United States. We are challenged with finding the optimal treatment for patient subgroups in a real-world setting. Treatment options have expanded to include immunotherapies versus platinum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41ab2565fea68ac4fbd02d52dd2f3db0
https://doi.org/10.6004/jnccn.2018.7114
https://doi.org/10.6004/jnccn.2018.7114
Publikováno v:
Journal of Clinical Oncology. 38:302-302
302 Background: Myeloid growth factors (MGF) are used to prevent and treat febrile neutropenia caused by immunosuppressive therapy. In the curative setting, the use of a full dose-intensity chemotherapy plus an MGF are recommended based on the febril
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::324342906cdd4f2b26af32ddcdb14400
https://doi.org/10.1200/jco.2020.38.29_suppl.302
https://doi.org/10.1200/jco.2020.38.29_suppl.302
Publikováno v:
Journal of Clinical Oncology. 37:269-269
269 Background: It is well known that one of the biggest challenges in the OCM is being able to reduce DS. DS accounts for approximately 50% of episode costs within OCM. New Century Health (NCH) is well known for its value-based care CPs, with a hist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ad4280e751c71e7c4a94ef005c7951b
https://doi.org/10.1200/jco.2019.37.27_suppl.269
https://doi.org/10.1200/jco.2019.37.27_suppl.269
Publikováno v:
Journal of Clinical Oncology. 36:e18925-e18925
e18925Background: ASCO released a policy statement in 2015 that stressed the synthesis of transparent and robust clinical pathways to abate treatment variability and incentivize the most cost-effec...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6609d389e8f8f2388f106c63be679200
https://doi.org/10.1200/jco.2018.36.15_suppl.e18925
https://doi.org/10.1200/jco.2018.36.15_suppl.e18925
Publikováno v:
Journal of Clinical Oncology. 34:166-166
166 Background: There is a need to improve palliative care program access for patients with cancer. The identification of candidates for palliative care at the point of diagnose can improve care and reduce costs. This pilot program was launched in Ju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93141238a238ec4fe845ea398cb5b6e3
https://doi.org/10.1200/jco.2016.34.7_suppl.166
https://doi.org/10.1200/jco.2016.34.7_suppl.166
Publikováno v:
Cancer Investigation. 9:211-219
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0ac32127f222cbd18860573d1f4bb1
https://doi.org/10.3109/07357909109044231
https://doi.org/10.3109/07357909109044231
Autor:
Andrew Allan Hertler, Steven S. Larmon, Tracey Weisberg, Thomas H. Openshaw, Denis Brin Hammond, Christian A. Thomas
Publikováno v:
Journal of Clinical Oncology. 30:79-79
79 Background: Participation in the Quality Oncology Practice Initiative (QOPI) by members of the Northern New England Oncology Society (NNECOS) has been historically low (two practices consistently participating). A survey of members identified a la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e42e11da61dd52c70dcdefecd2cbb538
https://doi.org/10.1200/jco.2012.30.34_suppl.79
https://doi.org/10.1200/jco.2012.30.34_suppl.79
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 7(12)
Immunotoxins are a new class of antitumor agents consisting of tumor-selective ligands (generally monoclonal antibodies [MoAbs]) linked to highly toxic protein molecules that have been modified to remove their normal tissue-binding domains. These imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75708ac15a54c216c6727faed6a58105
https://pubmed.ncbi.nlm.nih.gov/2685183
https://pubmed.ncbi.nlm.nih.gov/2685183